VIGORous Debate Continues In NEJM Over Propriety Of Merck’s Vioxx Study
Executive Summary
Merck's Vioxx VIGOR trial results do not need to be corrected, authors of the study assert in letters to the editors of the New England Journal of Medicine Feb. 22